Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lorente

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
European Urology Oncology|June 19, 2018
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate CancersPasquale Rescigno, David Lorente, David Dolling, et al.
Neuro-Oncology Advances|May 31, 2021
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastomaMustafa Khasraw, Michael Weller, David Lorente, et al.
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Radiology|October 1, 2020
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomasElies Fuster-Garcia, David Lorente Estellés, María Del Mar Álvarez-Torres, et al.
Clinical Genitourinary Cancer|June 2, 2016
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular AnalysesDavid Lorente, Aurelius Omlin, Zafeiris Zafeiriou, et al.
Plos One|December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinomaBert H O'Neil, John M Wallmark, David Lorente, et al.
European Urology|March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate CancerPasquale Rescigno, David Lorente, Diletta Bianchini, et al.
Radiology|November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot StudyRaquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
European Urology Oncology|June 19, 2018
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate CancersPasquale Rescigno, David Lorente, David Dolling, et al.
Neuro-Oncology Advances|May 31, 2021
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastomaMustafa Khasraw, Michael Weller, David Lorente, et al.
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
European Radiology|October 1, 2020
MGMT methylation may benefit overall survival in patients with moderately vascularized glioblastomasElies Fuster-Garcia, David Lorente Estellés, María Del Mar Álvarez-Torres, et al.
Clinical Genitourinary Cancer|June 2, 2016
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular AnalysesDavid Lorente, Aurelius Omlin, Zafeiris Zafeiriou, et al.
Plos One|December 29, 2017
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinomaBert H O'Neil, John M Wallmark, David Lorente, et al.
European Urology|March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate CancerPasquale Rescigno, David Lorente, Diletta Bianchini, et al.
Radiology|November 23, 2016
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot StudyRaquel Perez-Lopez, Joaquin Mateo, Helen Mossop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
European Urology|December 3, 2014
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetateRoberta Ferraldeschi, Daniel Nava Rodrigues, Ruth Riisnaes, et al.
Pageof 8